智通财经APP获悉，香港联交所最新资料显示，5月14日，科济药业-B(02171)股东将股票存入UBS Securities Hong Kong，存仓市值19.27亿港元，占比14.5%。
科济药业-B发布公告，于2026年5月15日(交易时段前)，公司、卖方益杰生物技术控股有限公司及联席配售代理订立配售协议，据此，卖方同意出售，而联席配售代理同意担任卖方的代理，并基于最大努力促使不少于六名承配人以每股配售股份19.84港元的配售价购买不超过2370万股配售股份。
智通财经APP获悉，香港联交所最新资料显示，5月14日，科济药业-B(02171)股东将股票存入UBS Securities Hong Kong，存仓市值19.27亿港元，占比14.5%。
科济药业-B发布公告，于2026年5月15日(交易时段前)，公司、卖方益杰生物技术控股有限公司及联席配售代理订立配售协议，据此，卖方同意出售，而联席配售代理同意担任卖方的代理，并基于最大努力促使不少于六名承配人以每股配售股份19.84港元的配售价购买不超过2370万股配售股份。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.